Literature DB >> 18424785

Estimating time-to-event from longitudinal ordinal data using random-effects Markov models: application to multiple sclerosis progression.

Micha Mandel1, Rebecca A Betensky.   

Abstract

Longitudinal ordinal data are common in many scientific studies, including those of multiple sclerosis (MS), and are frequently modeled using Markov dependency. Several authors have proposed random-effects Markov models to account for heterogeneity in the population. In this paper, we go one step further and study prediction based on random-effects Markov models. In particular, we show how to calculate the probabilities of future events and confidence intervals for those probabilities, given observed data on the ordinal outcome and a set of covariates, and how to update them over time. We discuss the usefulness of depicting these probabilities for visualization and interpretation of model results and illustrate our method using data from a phase III clinical trial that evaluated the utility of interferon beta-1a (trademark Avonex) to MS patients of type relapsing-remitting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18424785      PMCID: PMC2536724          DOI: 10.1093/biostatistics/kxn008

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  9 in total

1.  A mixed model for two-state Markov processes under panel observation.

Authors:  R J Cook
Journal:  Biometrics       Date:  1999-09       Impact factor: 2.571

2.  A conditional Markov model for clustered progressive multistate processes under incomplete observation.

Authors:  Richard J Cook; Grace Y Yi; Ker-Ai Lee; Dafna D Gladman
Journal:  Biometrics       Date:  2004-06       Impact factor: 2.571

3.  A two-state Markov chain for heterogeneous transitional data: a quasi-likelihood approach.

Authors:  P S Albert; M A Waclawiw
Journal:  Stat Med       Date:  1998-07-15       Impact factor: 2.373

4.  A logistic-bivariate normal model for overdispersed two-state Markov processes.

Authors:  R J Cook; E T Ng
Journal:  Biometrics       Date:  1997-03       Impact factor: 2.571

5.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-12       Impact factor: 13.501

6.  A Markov model for sequences of ordinal data from a relapsing-remitting disease.

Authors:  P S Albert
Journal:  Biometrics       Date:  1994-03       Impact factor: 2.571

7.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group.

Authors:  R A Rudick; E Fisher; J C Lee; J Simon; L Jacobs
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

8.  Estimating Time to Event From Longitudinal Categorical Data: An Analysis of Multiple Sclerosis Progression.

Authors:  Micha Mandel; Susan A Gauthier; Charles R G Guttmann; Howard L Weiner; Rebecca A Betensky
Journal:  J Am Stat Assoc       Date:  2007-12       Impact factor: 5.033

9.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

  9 in total
  6 in total

Review 1.  Estimation and assessment of markov multistate models with intermittent observations on individuals.

Authors:  J F Lawless; N Nazeri Rad
Journal:  Lifetime Data Anal       Date:  2014-10-21       Impact factor: 1.588

2.  Estimating time to disease progression comparing transition models and survival methods--an analysis of multiple sclerosis data.

Authors:  Micha Mandel; Francois Mercier; Benjamin Eckert; Peter Chin; Rebecca A Betensky
Journal:  Biometrics       Date:  2013-02-14       Impact factor: 2.571

3.  Semiparametric Mixed Effect Model with Application to the Longitudinal Knee Osteoarthritis (OAK) Data.

Authors:  Huiyong Zheng; Maryfran Sowers; Carrie Karvonen-Gutierrez; Jon A Jacobson; John F Randolph; Siobàn D Harlow
Journal:  J Syst Cybern Inf       Date:  2012

4.  UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.

Authors:  Jacqueline Palace; Thomas Bregenzer; Helen Tremlett; Joel Oger; Feng Zhu; Fheng Zhu; Mike Boggild; Martin Duddy; Charles Dobson
Journal:  BMJ Open       Date:  2014-01-17       Impact factor: 2.692

Review 5.  GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world.

Authors:  Klea Panayidou; Sandro Gsteiger; Matthias Egger; Gablu Kilcher; Máximo Carreras; Orestis Efthimiou; Thomas P A Debray; Sven Trelle; Noemi Hummel
Journal:  Res Synth Methods       Date:  2016-08-16       Impact factor: 5.273

6.  Developing a clinical-environmental-genotypic prognostic index for relapsing-onset multiple sclerosis and clinically isolated syndrome.

Authors:  Valery Fuh-Ngwa; Yuan Zhou; Jac C Charlesworth; Anne-Louise Ponsonby; Steve Simpson-Yap; Jeannette Lechner-Scott; Bruce V Taylor
Journal:  Brain Commun       Date:  2021-12-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.